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1076-201 Relative Incidence of Thrombus Formation on the 
CardioSEAL and Amplatzer Interatrial Closure Devices
Hitoshi Anzai, Vicki K. Chan, Jonathan M. Tobis, Barbara Natterson, Janine Krivokapich, 
Michael C. Fishbein, John S. Child, University of California, Los Angeles, Los Angeles, 
CA
Background: Transcatheter closure for atrial septal defect (ASD) and patent foramen
ovale (PFO) is a promising alternative to surgical closure or anticoagulant therapy. A
potential complication is thrombus formation on the device after implantation. This study
compared the incidence of thrombus formation at one month post implant between the
two FDA approved devices.
Methods: From February 2001 through August 2003, 68 patients (50 PFO, 13 ASD and
5 fenestrated septum) were treated successfully with the Amplatzer device (19 septal and
18 PFO occluders) or the CardioSEAL device (30). Antiplatelet medication (aspirin and
clopidogrel) was prescribed for 6 months after the procedure. Fifty-two patients had
transesophageal echocardiography (TEE) one month after device implantation (26±9
days).
Results: No patient suffered a thromboembolic episode during the 30 month follow-up
period. TEE revealed that thrombus formation occurred more frequently on the Cardio-
SEAL device (5/23, 22%) than on the Amplatzer device (0/27, 0%) (p=0.02). The pres-
ence of thrombus on the device in the follow-up period was defined as a new
hypoechogenic nonplanar, partially mobile structure. Although thrombus disappeared or
diminished following additional warfarin therapy in 3 patients, one patient had surgical
explantation of the device due to progressive increase in the size of thrombus with hyper-
mobility despite additional therapy with warfarin and argatroban.
Conclusion: The CardioSEAL device is more likely to have thrombus formation one
month after insertion than the Amplatzer device. Most patients with thrombus on the
device had a benign clinical course due to thrombus resolution following anticoagulation
therapy. However, the high incidence of thrombus post implantation could explain the
presence of recurrent embolic events observed in prior clinical trials.
1076-202 Impact of Aortic Stenting on Blood Pressure in Adult 
Coarctation
Sylvia S. Chen, Ann E. Donald, Clare Storry, Natalie Lloyd, Amanda Deighan, Marietta 
Charakida, Saemus Cullen, Philipp Bonhoeffer, Julian Halcox, John E. Deanfield, Heart 
Hospital, London, United Kingdom, Institute of Child Health, London, United Kingdom
Background: In patients with coarctation (CoA), persistent hypertension is the major
cause of late morbidity and mortality. The relationships between obstruction, and more
widespread vascular abnormalities as well as their potential for recovery are unknown.
Methods: We measured blood pressure (BP) over 24-hours, during exercise, and bra-
chial-ankle systolic BP gradient in 11 patients (5 M, 6 F) pre- and 2-4 weeks post-stenting
of CoA. Endothelium-dependent flow-mediated dilatation (FMD), and endothelium-inde-
pendent dilation with nitroglycerine (GTN) were measured in the right brachial artery
using high-resolution ultrasound in patients and in 12 controls. Carotid-radial pulse-wave
velocity (PWV, arterial stiffness) was recorded.
Results: Prior to stenting, patients were hypertensive at rest and during exercise. Peak
CoA gradient after stenting was significantly reduced (32.3±18.3 pre, versus
10.9±10.9mmHg post, P=0.001). Brachial-ankle systolic BP gradient was reduced after
stenting (25.7±17.9 pre, versus 2.0±12.4mmHg post, p=0.02). Ambulatory BP (152±21 /
79±15 pre, versus 147±15 / 80±9mmHg post, p>0.7), mean pulse pressure (70±10 pre
versus 66±13mmHg post, p=0.6), and systolic BP at peak exercise (227±24 pre versus
225±21mmHg post, p=0.7) were unchanged. Baseline FMD was significantly impaired
compared with controls (4.2±0.6 versus 8.0±2.2% respectively, p=0.02) but unchanged
post-stent (4.4±3.1%, p=0.9). Response to GTN (7.3±2.2 pre versus 8.2±4.8% post,
p=0.7) and PWV (8.3±1.0 pre versus 8.4±1.2m/s post, p=0.4) were also unchanged.
Conclusion: Relief of the gradient in CoA does not result in an early change in blood
pressure. Persistently abnormal vascular function and stiffness are likely to contribute.
Long-term consequences on vascular remodelling and BP require study.
1076-203 Comparison of Surgical Repair With Balloon 
Angioplasty for Native Coarctation in Patients From 
Three Months to 16 Years of Age
Ronald J. Walhout, Jaco C. Lekkerkerker, Gordon H. Oron, Ger B.W.E Bennink, Erik J. 
Meijboom, University Hospital of Vaud, Lausanne, Switzerland, UMC Utrecht, Utrecht, 
The Netherlands
Objective
Surgery and balloon angioplasty for coarctation of the aorta have shown comparable
short-term results, but long-term follow-up remains unclear. Comparison of surgical
repair and balloon coarctation for native coarctation with a discrete localization is per-
formed retrospectively.To allow a valid comparison between both techniques, identical
inclusion criteria were applied.
Methods
Results of surgery (group A, 18 patients, age 0.30-14 years, median 0.63 years) and bal-
loon angioplasty (group B, 28 patients, age 0.25-15 years, median 5.8 years) for isolated,
native coarctation in children > 3 months, performed in a 10-year-period, were compared.
Kaplan-Meier analysis was performed in both groups. Mean follow-up ranged from 2.5 to
11 years (mean 7.2 ± 2.4 years) in group A and from 1.4 to 10 years (mean 5.4 ± 2.8
years) in group B.
Results
Immediate success was obtained in all patients following surgery and 27/28 patients
(96%) following balloon angioplasty. No statistical difference between surgery and angio-
plasty with respect to resultant pressure gradient decreases were found. Mortality was
not encountered., Hospital stay varied from 6 to 20 days in group A and was 48 hours for
all patients in group B. Recoarctation occurred in 1 patient (5.6%) in group A and in 2
patients (7%) in group B. Log-rank test reveals no statistical difference in freedom from
reintervention probabilities between surgery and angioplasty. Aneurysm formation was
not encountered.
Conclusions
Surgical repair and balloon angioplasty for native coarctation yield comparable reinter-
vention probabilities in comparable patients. Aneurysm formation was not encountered
following different treatment types.
1076-204 Transcatheter Patch Occlusion of Perimembranous 
Ventricular Septal Defects in Surgical Candidates
Eleftherios B. Sideris, Benjamin Macuil, Victor Varvarenko, Savvas Toumanides, 
Athenian Institute of Pediatric Cardiology, Athens, Greece, University of Texas, Houston, 
TX
Background: Perimembranous ventricular septal defect(VSD)is a challenging lesion
because of its proximity to critical structures(aortic valve, tricuspid valve). Non-restrictive
VSDs including mal-alignment ones are managed predominently by Surgery. The tran-
scatheter patch(TP) is a balloon inflatable device requiring 24-48 hour support, before
release. It is wireless and requires minimal subaortic rim; it could be therefore applicable
for the above VSDs.
Methods: Sixteen consecutive surgical candidates for VSD correction were brought to
the cath-lab for TP occlusion. There were 3 cases of non-restrictive VSDs including 2
malalignment ones(Fallot-Tetralogy).
All cases except for the Fallot Tetralogy cases which were cyanotic had large L-R
shunts(Qp:Qs>2:1). Patient age varied between 2-35 years (med.7) and VSD size
between 5-20 mm (med.12). They were occluded by 8 single and 8 double balloon/
patches (15 nylon, 1 latex balloon). All VSDs were corrected through the femoral vein;
four were crossed antegrade and 12 retrograde.
Results: All VSDs with the exception of 2 were successfully occluded (12 full occlusions,
2 trivial shunts). On follow-up (up to 3 years) there were no embolizations, aortic insuffi-
ciency(AI) or other late complications. In one case with aortic cusp prolapse and balloon
related AI the patch was electively withdrawn. However, in a subsequent similar case, the
balloon/patch was left in place despite the AI; upon patch release there was full occlusion
and no AI. A 20 mm VSD was occluded by a large double latex balloon/patch; the balloon
was ruptured the first 24 hours and was retracted. There was a case of ventricular fibrilla-
tion on implantation, which required acute cardioversion; however there was excellent
final result, with full occlusion and no AI.
Conclusions: TP occlusion of VSDs in surgical candidates is effective and relatively
safe. Expansion of the method to the infant VSD group could challenge the current surgi-
cal standard of treatment.
1076-205 Use of Amplatzer Duct Occluder for Complex 
Congenital Cardiac Lesions: Results From the US 
Registry Group
Zahid Amin, Ziyad M. Hijazi, Chen Chan, Makram Ebeid, Wolfgang Radtke, Frank Ing, 
Satinder Sandhu, Thomas Zellars, University of Nebraska, Omaha, NE
Background: The Amplatzer Duct occluder (ADO) is suitable for several complex con-
genital cardiac lesions. The ADO registry group was established for patients (pts) who
received the device for complex lesions other than patent ductus arteriosus (PDA). We
reviewed the registry pts to assess the efficacy of ADO. Methods: The pts were divided
into two groups: pts with complex lesions (e.g., pulmonary arteriovenous malformation,
coronary artery fistulas, veno-venous collaterals, etc.), and pts with severe medical con-
dition (pts who needed surgery, but the risk of surgery was unacceptable) as paravalvular
leaks, large PDA in pts with associated cardiac lesions (Table). Results: The overall suc-
cess rate was 83%. Of the 42 pts with complex disease (mean weight 32 kg, range 3.5-
92 kg), device placement was attempted in 34 with successful placement in all pts. Com-
plete closure at six months follow up was 100%. One device embolized without any
sequelae. In the severe medical condition (mean weight 16 kg, range 3.0-79 kg), place-
ment was successful in 87% of pts in whom device placement was attempted. Complete
closure rate at the last follow up was 94%. Two pts required surgery because of residual
defects. There were 3 deaths in this group, none were related to the device or the proce-
dure. Conclusions: The ADO appears to be an ideal device for complex congenital car-
diac lesions with success rate of 100%. It can also be used as a therapeutic or bail out
procedure in pts who are high risk candidates for surgery . Registry Distribution 
Diagnosis # of pts Placement
Attempted
Placement
NOT Attempted
Success Rate
Coronary artery Fistula 12 6 6 100%
Pulmonary AVM 9 9 0 100%
Aorto-pulmonary collateral 3 2 1 100%
Veno-venous collateral 8 7 1 100%
Extracardiac Fenestration 4 4 0 100%
Blalock-Taussig Shunt 6 6 0 100%
Severe Medical Conditions 35 30 5 86%
Total 77 64 13 83%
